logo
logo

AbbVie to acquire Cerevel Therapeutics for $45/share

Apr 07, 2025•4 months ago

Acquiring Company

Cerevel Therapeutics Holdings

Acquired Company

Cerevel Therapeutics Holdings

North ChicagoNorth Chicago

Description

AbbVie Inc. has announced its plan to acquire Cerevel Therapeutics Holdings, Inc. at a price of $45 per share. This acquisition follows a secondary stock offering by Cerevel that was organized by Bain and Pfizer. The market was misled by the misleading statements from Cerevel regarding this acquisition plan. Investors are encouraged to participate in the class action lawsuit regarding this matter.

Company Information

Company

Cerevel Therapeutics Holdings

Location

North Chicago, Illinois, United States

About

Cerevel Therapeutics is a biopharmaceutical company dedicated to developing therapies for neuroscience. It focuses on curing diseases associated with the central nervous system, specializing in treating disorders such as schizophrenia and epilepsy. Cerevel is known for its innovative approaches to complex neurological conditions. The company went public and was listed on NASDAQ under the ticker symbol CERE.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed